Aquestive Historical Balance Sheet

AQST Stock

USD 2.80 0.16 5.41%

Trend analysis of Aquestive Therapeutics balance sheet accounts such as Other Current Liab of 6.8 M, Total Current Liabilities of 20 M or Accounts Payable of 9.4 M provides information on Aquestive Therapeutics' total assets, liabilities, and equity, which is the actual value of Aquestive Therapeutics to its prevalent stockholders. By breaking down trends over time using Aquestive Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Aquestive Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Aquestive Therapeutics is a good buy for the upcoming year.

Aquestive Therapeutics Inventory

8.17 Million

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aquestive Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more information on how to buy Aquestive Stock please use our How to Invest in Aquestive Therapeutics guide.

About Aquestive Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Aquestive Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Aquestive Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Aquestive Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Aquestive currently owns. An asset can also be divided into two categories, current and non-current.

Aquestive Therapeutics Balance Sheet Chart

At this time, Aquestive Therapeutics' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Other Current Assets is likely to gain to about 3 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 20 M in 2025.

Total Assets Other Current Liab Total Current Liabilities Accounts Payable

Add Fundamental

Total Assets

Total assets refers to the total amount of Aquestive Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Aquestive Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Aquestive Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Aquestive Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Aquestive Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Aquestive Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from Aquestive Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Aquestive Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aquestive Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more information on how to buy Aquestive Stock please use our How to Invest in Aquestive Therapeutics guide.At this time, Aquestive Therapeutics' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Other Current Assets is likely to gain to about 3 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 20 M in 2025.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	8.8M	7.1M	8.1M	6.8M
Total Assets	55.7M	57.4M	66.0M	57.8M

Other Current Liab Total Assets

Aquestive Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Other Assets	Long Term Debt	Net Receivables	Inventory	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Other Liab	Cash And Short Term Investments	Short Long Term Debt Total	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Non Current Assets Total
Total Assets		0.78	0.76	-0.28	0.23	-0.42	0.87	0.95	0.19	0.59	0.28	0.55	0.59	-0.52	0.99	-0.47	-0.32	-0.83	-0.38	0.36	0.87	-0.8	-0.69	0.16	-0.81	-0.39
Other Current Liab	0.78		0.82	-0.7	-0.13	-0.77	0.51	0.67	0.63	0.33	0.1	0.61	0.86	-0.56	0.73	-0.5	-0.11	-0.88	-0.66	0.71	0.59	-0.88	-0.88	0.35	-0.52	0.08
Total Current Liabilities	0.76	0.82		-0.54	-0.02	-0.58	0.73	0.75	0.47	0.3	-0.12	0.61	0.71	-0.4	0.74	-0.38	0.03	-0.76	-0.44	0.53	0.69	-0.73	-0.74	0.38	-0.53	-0.18
Total Stockholder Equity	-0.28	-0.7	-0.54		0.6	0.98	-0.04	-0.14	-0.39	0.06	0.05	-0.74	-0.89	0.42	-0.21	0.37	-0.38	0.62	0.65	-0.96	-0.09	0.66	0.79	-0.74	0.07	-0.42
Net Tangible Assets	0.23	-0.13	-0.02	0.6		0.57	0.27	0.46	-0.04	-0.04	-0.29	-0.4	-0.4	-0.44	0.33	-0.35	-0.03	-0.16	-0.17	-0.45	0.59	-0.06	0.07	-0.54	-0.47	-0.55
Retained Earnings	-0.42	-0.77	-0.58	0.98	0.57		-0.15	-0.26	-0.37	-0.1	-0.1	-0.78	-0.93	0.44	-0.35	0.38	-0.25	0.7	0.63	-0.95	-0.19	0.73	0.84	-0.71	0.17	-0.32
Accounts Payable	0.87	0.51	0.73	-0.04	0.27	-0.15		0.89	-0.07	0.52	0.11	0.52	0.34	-0.28	0.88	-0.34	-0.29	-0.57	-0.08	0.12	0.82	-0.58	-0.41	0.14	-0.79	-0.51
Cash	0.95	0.67	0.75	-0.14	0.46	-0.26	0.89		0.16	0.49	0.05	0.45	0.43	-0.6	0.98	-0.58	-0.22	-0.8	-0.42	0.25	0.98	-0.77	-0.64	0.07	-0.85	-0.53
Other Assets	0.19	0.63	0.47	-0.39	-0.04	-0.37	-0.07	0.16		0.09	-0.13	-0.1	0.41	-0.21	0.16	-0.19	-0.1	-0.38	-0.5	0.29	0.14	-0.33	-0.47	-0.08	0.1	0.16
Long Term Debt	0.59	0.33	0.3	0.06	-0.04	-0.1	0.52	0.49	0.09		0.73	0.12	0.12	0.16	0.59	0.07	-0.8	-0.21	0.17	-0.1	0.35	-0.15	-0.24	-0.2	-0.13	-0.58
Net Receivables	0.28	0.1	-0.12	0.05	-0.29	-0.1	0.11	0.05	-0.13	0.73		0.01	0.09	0.29	0.24	0.44	-0.68	0.02	0.35	-0.1	-0.11	0.11	0.03	-0.21	0.1	-0.2
Inventory	0.55	0.61	0.61	-0.74	-0.4	-0.78	0.52	0.45	-0.1	0.12	0.01		0.74	-0.41	0.5	-0.43	0.21	-0.64	-0.41	0.83	0.4	-0.72	-0.68	0.74	-0.5	0.18
Total Liab	0.59	0.86	0.71	-0.89	-0.4	-0.93	0.34	0.43	0.41	0.12	0.09	0.74		-0.5	0.52	-0.44	0.24	-0.77	-0.65	0.86	0.36	-0.82	-0.86	0.72	-0.34	0.24
Short Long Term Debt	-0.52	-0.56	-0.4	0.42	-0.44	0.44	-0.28	-0.6	-0.21	0.16	0.29	-0.41	-0.5		-0.55	0.82	-0.38	0.84	0.89	-0.58	-0.7	0.79	0.74	-0.22	0.65	0.06
Total Current Assets	0.99	0.73	0.74	-0.21	0.33	-0.35	0.88	0.98	0.16	0.59	0.24	0.5	0.52	-0.55		-0.5	-0.3	-0.82	-0.39	0.3	0.92	-0.78	-0.67	0.11	-0.81	-0.49
Short Term Debt	-0.47	-0.5	-0.38	0.37	-0.35	0.38	-0.34	-0.58	-0.19	0.07	0.44	-0.43	-0.44	0.82	-0.5		-0.31	0.68	0.82	-0.49	-0.67	0.78	0.7	-0.4	0.58	0.12
Intangible Assets	-0.32	-0.11	0.03	-0.38	-0.03	-0.25	-0.29	-0.22	-0.1	-0.8	-0.68	0.21	0.24	-0.38	-0.3	-0.31		-0.12	-0.43	0.4	-0.09	-0.15	-0.18	0.57	0.05	0.32
Common Stock	-0.83	-0.88	-0.76	0.62	-0.16	0.7	-0.57	-0.8	-0.38	-0.21	0.02	-0.64	-0.77	0.84	-0.82	0.68	-0.12		0.79	-0.71	-0.8	0.94	0.93	-0.34	0.7	0.12
Property Plant Equipment	-0.38	-0.66	-0.44	0.65	-0.17	0.63	-0.08	-0.42	-0.5	0.17	0.35	-0.41	-0.65	0.89	-0.39	0.82	-0.43	0.79		-0.72	-0.5	0.78	0.85	-0.37	0.36	-0.11
Other Liab	0.36	0.71	0.53	-0.96	-0.45	-0.95	0.12	0.25	0.29	-0.1	-0.1	0.83	0.86	-0.58	0.3	-0.49	0.4	-0.71	-0.72		0.23	-0.75	-0.83	0.72	-0.26	0.43
Cash And Short Term Investments	0.87	0.59	0.69	-0.09	0.59	-0.19	0.82	0.98	0.14	0.35	-0.11	0.4	0.36	-0.7	0.92	-0.67	-0.09	-0.8	-0.5	0.23		-0.75	-0.63	0.05	-0.86	-0.54
Short Long Term Debt Total	-0.8	-0.88	-0.73	0.66	-0.06	0.73	-0.58	-0.77	-0.33	-0.15	0.11	-0.72	-0.82	0.79	-0.78	0.78	-0.15	0.94	0.78	-0.75	-0.75		0.91	-0.52	0.74	0.0
Property Plant And Equipment Net	-0.69	-0.88	-0.74	0.79	0.07	0.84	-0.41	-0.64	-0.47	-0.24	0.03	-0.68	-0.86	0.74	-0.67	0.7	-0.18	0.93	0.85	-0.83	-0.63	0.91		-0.51	0.45	0.04
Current Deferred Revenue	0.16	0.35	0.38	-0.74	-0.54	-0.71	0.14	0.07	-0.08	-0.2	-0.21	0.74	0.72	-0.22	0.11	-0.4	0.57	-0.34	-0.37	0.72	0.05	-0.52	-0.51		-0.13	0.35
Net Debt	-0.81	-0.52	-0.53	0.07	-0.47	0.17	-0.79	-0.85	0.1	-0.13	0.1	-0.5	-0.34	0.65	-0.81	0.58	0.05	0.7	0.36	-0.26	-0.86	0.74	0.45	-0.13		0.22
Non Current Assets Total	-0.39	0.08	-0.18	-0.42	-0.55	-0.32	-0.51	-0.53	0.16	-0.58	-0.2	0.18	0.24	0.06	-0.49	0.12	0.32	0.12	-0.11	0.43	-0.54	0.0	0.04	0.35	0.22

Click cells to compare fundamentals

Aquestive Therapeutics Account Relationship Matchups

Aquestive Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	62.9M	62.0M	55.7M	57.4M	66.0M	57.8M
Other Current Liab	9.7M	9.6M	8.8M	7.1M	8.1M	6.8M
Total Current Liabilities	21.1M	22.0M	39.7M	18.3M	21.1M	20.0M
Total Stockholder Equity	(48.5M)	(82.1M)	(118.6M)	(106.5M)	(95.8M)	(91.0M)
Net Tangible Assets	(6.3M)	(48.6M)	(82.2M)	(120.0M)	(108.0M)	(102.6M)
Retained Earnings	(186.3M)	(256.8M)	(311.2M)	(319.1M)	(287.2M)	(272.8M)
Accounts Payable	7.1M	8.3M	9.9M	8.9M	10.3M	9.4M
Cash	31.8M	28.0M	27.3M	23.9M	27.5M	29.0M
Other Assets	7.8M	6.9M	6.5M	1.0	1.15	1.09
Long Term Debt	34.3M	51.6M	33.4M	27.5M	31.6M	41.5M
Net Receivables	7.0M	12.1M	4.7M	8.5M	9.7M	7.7M
Inventory	2.5M	4.0M	5.8M	6.8M	7.8M	8.2M
Total Liab	111.4M	144.1M	174.2M	163.9M	188.5M	98.0M
Total Current Assets	44.6M	47.3M	39.9M	41.0M	47.1M	42.4M
Intangible Assets	102K	51K	1.4M	1.3M	1.2M	587.7K
Common Stock	35K	41K	55K	69K	62.1K	59.0K
Property Plant Equipment	9.7M	6.9M	5.1M	7.9M	7.1M	7.7M
Other Liab	5.7M	53.1M	68.7M	97.6M	112.2M	117.8M
Cash And Short Term Investments	31.8M	28.0M	27.3M	23.9M	27.5M	32.1M
Short Long Term Debt Total	40.5M	56.4M	56.1M	33.3M	30.0M	49.9M
Property Plant And Equipment Net	10.3M	7.8M	7.9M	9.7M	8.8M	8.6M
Current Deferred Revenue	693K	765K	1.5M	1.6M	1.8M	1.1M
Net Debt	8.7M	28.4M	28.8M	9.4M	8.5M	13.1M
Non Current Assets Total	18.3M	14.7M	15.8M	16.5M	18.9M	16.4M
Non Currrent Assets Other	7.8M	6.9M	6.5M	5.4M	6.3M	4.0M
Common Stock Shares Outstanding	33.7M	38.1M	48.7M	61.3M	70.4M	37.4M
Liabilities And Stockholders Equity	62.9M	62.0M	55.7M	57.4M	66.0M	66.8M
Non Current Liabilities Total	90.3M	122.2M	134.6M	145.6M	167.4M	96.6M
Other Current Assets	6.8M	6.2M	2.1M	1.9M	2.1M	3.0M
Other Stockholder Equity	137.7M	174.6M	192.6M	212.5M	244.4M	142.2M
Property Plant And Equipment Gross	10.3M	7.8M	7.9M	52.6M	60.5M	63.5M
Net Invested Capital	(11.6M)	(28.6M)	(66.4M)	(79.0M)	(71.1M)	(67.5M)
Net Working Capital	23.5M	25.3M	209K	22.7M	20.4M	20.1M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Aquestive Stock Analysis

When running Aquestive Therapeutics' price analysis, check to measure Aquestive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aquestive Therapeutics is operating at the current time. Most of Aquestive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aquestive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aquestive Therapeutics' price. Additionally, you may evaluate how the addition of Aquestive Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Aquestive Historical Balance Sheet

Aquestive Therapeutics Inventory

8.17 Million

About Aquestive Balance Sheet Analysis

Aquestive Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Accounts Payable

Aquestive Therapeutics balance sheet Correlations

Aquestive Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Aquestive Therapeutics balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Aquestive Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Total Assets
Retained Earnings	+ 0.98	Total Stockholder Equity
Total Current Assets	+ 0.98	Cash
Cash And Short Term Investments	+ 0.98	Cash
Cash	+ 0.95	Total Assets
Short Long Term Debt Total	+ 0.94	Common Stock

Other Liab	- 0.96	Total Stockholder Equity
Other Liab	- 0.95	Retained Earnings
Total Liab	- 0.93	Retained Earnings
Total Liab	- 0.89	Total Stockholder Equity
Property Plant And Equipment Net	- 0.88	Other Current Liab
Short Long Term Debt Total	- 0.88	Other Current Liab